DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care

Source: TheStreet· Nrx Pharmaceuticals· July 24, 2026
DARPA Selects NRx Pharmaceuticals Defense Subsidiary for Contract Negotiations on FDA-Authorized SPARC-TMS Clinical Trial Advancing Mental Health Care

Potential DARPA Award, FDA-Authorized Phase 2/3 Trial, Breakthrough Therapy NRX-101, and Robotic-Enabled TMS Platform Highlight Expanding Opportunities for NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) MIAMI - July 22, 2026 - PRLog -- DARPA Selects NRx Defens…

This story was reported by TheStreet. Read the full original article:
Read on TheStreet

More in Products & Launches

View all